In 2020, NHS Business Services Authority data showed that over 8 million patients in England received antidepressant prescriptions, a number that had grown by roughly 35% since 2010. The reasons are complex: longer treatment duration, greater recognition of depression, and perhaps a healthcare system that finds it easier to write a prescription than to offer a therapy session. Yet the rise has not been matched by equivalent access to psychological therapies, and a quiet controversy persists among clinicians, policymakers, and patients about what first-line treatment for depression should look like.

The National Institute for Health and Care Excellence (NICE) has long recommended that talking therapies, such as cognitive behavioural therapy (CBT), be offered alongside medication for moderate to severe depression. In practice, that ideal often falls short. Therapy wait times vary dramatically by region, and many patients never receive a referral at all. Meanwhile, general practitioners (GPs) working in ten-minute appointments say they lack the time to explore treatment options thoroughly. The result is a system where medication often becomes the default, even when patients would prefer to talk.

Rising Prescription Rates Mask Uneven Access

Antidepressant prescribing in England has increased from around 40 million items per year in 2010 to roughly 55 million by 2020, a rise of about 35%. The number of patients receiving antidepressants now exceeds 8 million, according to NHS Business Services Authority data. This growth is not simply a reflection of rising depression prevalence; it also reflects longer treatment durations. Many patients remain on antidepressants for years, and some for decades, often without regular review.

The increase has been particularly marked in deprived areas. Prescribing rates in the most deprived fifth of England are roughly double those in the least deprived fifth. This pattern raises questions about whether medication is being used as a substitute for therapy, which is often harder to access in poorer communities. A 2019 study in the British Journal of General Practice found that GPs in deprived areas were more likely to prescribe antidepressants and less likely to refer for therapy, even after adjusting for patient need.

NICE guidelines recommend that antidepressant treatment be accompanied by psychological therapy for moderate to severe depression. Yet data from NHS Digital suggest that only about one in three patients referred for therapy actually receive it. The gap between recommendation and reality is wide, and it is not closing quickly. Some commentators argue that the rise in prescribing reflects a systemic failure to invest in talking therapies, leaving medication as the only readily available option.

Others counter that antidepressants are effective and that the rise in prescribing simply means more people are getting treatment. A 2021 meta-analysis in The Lancet confirmed that antidepressants are more effective than placebo for moderate to severe depression, though the effect size is modest. The controversy, then, is not about whether antidepressants work, but about whether they are being used appropriately—and whether the system is offering patients a real choice.

Therapy Wait Times: A Postcode Lottery

The NHS Talking Therapies programme, formerly known as IAPT (Improving Access to Psychological Therapies), was launched in 2008 with the aim of providing evidence-based psychological therapies to people with depression and anxiety disorders. By 2024, the programme was seeing around 1.2 million referrals per year. Yet access remains deeply uneven. Some clinical commissioning groups (now integrated care boards) report median wait times of under four weeks for a first appointment, while others exceed 18 weeks.

Referral criteria also vary. Some trusts require patients to score above a certain threshold on a depression or anxiety questionnaire before they can be accepted. Others exclude people with comorbid conditions such as substance use or personality disorders. This creates a patchwork of access where a patient's postcode can determine whether they receive therapy within a reasonable time—or at all.

For those who cannot wait, private therapy offers an alternative, but at a cost. Sessions typically range from £40 to £80 per hour, and many therapists recommend a course of at least eight to twelve sessions. For someone on a median income, that represents a significant outlay. Low-cost options exist through charities and voluntary organisations, but they are often oversubscribed and may have their own waiting lists.

The consequence is that many patients who would prefer therapy end up accepting medication as a faster, more accessible option. A 2022 survey by the charity Mind found that 42% of people who had sought therapy said they had been offered antidepressants instead. The same survey reported that two-thirds of respondents felt they had not been given enough information about treatment options. The postcode lottery is not just about geography; it is about information, time, and the structure of primary care.

Experts Disagree on First-Line Treatment Priority

Within the mental health community, there is no consensus on whether antidepressants or therapy should be the default first step for moderate depression. Some clinicians argue that therapy should be offered first, because it addresses underlying cognitive and behavioural patterns, has fewer side effects, and may produce longer-lasting benefits. A 2015 meta-analysis in JAMA Psychiatry found that CBT was as effective as antidepressants for acute depression and had lower relapse rates at follow-up.

Others maintain that medication should be first-line because it works faster, is more scalable, and can enable a patient to engage with therapy who might otherwise be too depressed to participate. Dr. David Richards, a professor of mental health services research at the University of Exeter, has argued that antidepressants are “an essential part of the treatment pathway” and that delaying medication while a patient waits for therapy can prolong suffering. The NICE guideline update of 2022 attempted to strike a balance, recommending that both options be discussed, but the ambiguity has left room for interpretation.

The evidence base itself is contested. Randomised controlled trials (RCTs) of antidepressants often show modest superiority over placebo, but critics note that the placebo response in depression trials is large, and that publication bias may inflate apparent efficacy. Similarly, RCTs of therapy are difficult to blind, and therapist effects can confound results. A 2018 network meta-analysis in The Lancet Psychiatry found that some antidepressants were more acceptable than others, but that the differences between drug and therapy outcomes were small.

Given these uncertainties, the controversy is unlikely to be resolved by more trials alone. It reflects deeper disagreements about what depression is—a brain disorder, a response to life circumstances, or both—and about what the healthcare system should prioritise: speed of access, depth of treatment, or patient preference. The NICE guideline, while evidence-based, leaves enough ambiguity for clinicians to justify very different approaches.

GP Prescribing Patterns Under Scrutiny

General practitioners are the gatekeepers of both antidepressant prescriptions and therapy referrals. Their decisions are shaped by time constraints, training, and local availability of services. A typical GP appointment lasts ten minutes, which many doctors say is insufficient to explore a patient's mental health history, discuss treatment options, and arrange a therapy referral. As a result, prescribing becomes the path of least resistance.

Prescribing rates are highest in the most deprived areas, where GPs often have larger patient lists and fewer local therapy services. A 2020 report by the Royal College of General Practitioners found that GPs in deprived areas were more likely to prescribe antidepressants because they had “fewer alternatives to offer”. The same report noted that only about one in three patients referred for therapy actually receive it, suggesting that the referral itself is no guarantee of treatment.

Antidepressant withdrawal effects have also come under scrutiny. A 2023 review in the Journal of Affective Disorders estimated that roughly half of people who attempt to stop antidepressants experience withdrawal symptoms, which can include dizziness, nausea, and emotional distress. NICE guidelines acknowledge the risk but do not mandate specific monitoring protocols. Many patients report being unaware of withdrawal effects when they started medication, and some describe feeling “trapped” on pills they no longer want to take.

The Royal College of Psychiatrists has called for better guidance on tapering and for GPs to discuss withdrawal risks at the point of prescribing. Yet in a ten-minute consultation, such conversations are often squeezed out. The scrutiny of GP prescribing patterns is not about blaming individual doctors; it is about a system that incentivises quick fixes over thorough care.

NHS Workforce Shortages Deepen the Divide

The NHS Talking Therapies workforce has grown substantially since 2008, from roughly 3,000 therapists to around 10,000 by 2024. Yet the expansion has not kept pace with demand. The number of referrals has grown faster than the number of therapists, leading to longer waiting lists in many areas. The NHS Long Term Plan, published in 2019, pledged to expand access to talking therapies so that 1.9 million people per year could be treated by 2024. That target has not been met.

Burnout among therapists is a growing concern. High caseloads, administrative burden, and exposure to patient distress contribute to attrition. A 2022 survey by the British Association for Behavioural and Cognitive Psychotherapies found that nearly half of therapists reported feeling “burnt out” or “at risk of burnout”. Some leave the NHS for private practice, where they can earn more and control their caseload. This exodus further strains the public system.

The private sector has grown alongside the NHS, offering therapy to those who can afford it. But this creates a two-tier system in which affluent patients can access timely care while those on lower incomes wait. Some NHS therapists also work privately, reducing their availability for public patients. The net effect is that the workforce shortage deepens the divide between those who can pay and those who cannot.

Innovations such as online CBT and guided self-help have been promoted as partial solutions. NHS Talking Therapies now offers digital options, and evidence suggests they can be effective for mild to moderate depression. But digital therapies are not a panacea; they require reliable internet access, digital literacy, and a degree of self-motivation that not all patients possess. For severe depression, face-to-face therapy remains the gold standard, and the workforce shortage means many patients cannot access it.

Patient Perspectives: Trade-Offs in Real Life

For patients, the choice between medication and therapy is rarely straightforward. Many express a preference for therapy but accept pills because they are faster and more convenient. Sarah, a 34-year-old teacher from Manchester, told the charity Rethink Mental Illness: “I would have liked to talk to someone, but the waiting list was six months. My GP said I could start antidepressants straight away, so I did.” Others find that medication helps them function well enough to engage in therapy later, creating a stepwise pathway that can work.

Shared decision-making—where clinician and patient discuss options together—is often absent in rushed consultations. A 2021 study in the British Journal of General Practice found that fewer than one in three patients reported being involved in decisions about their antidepressant treatment. Many said they felt “talked into” medication, while others said they were not told about side effects or withdrawal risks. The lack of shared decision-making can erode trust and lead to poor adherence or premature discontinuation.

Support groups and peer support offer an alternative or adjunct to formal therapy. Organisations such as Mind and the Samaritans provide helplines and local groups where people can share experiences. Online communities, including forums on platforms like HealthUnlocked, allow patients to discuss treatment options and side effects. These resources are valuable, but they are not a substitute for professional care, and their quality varies widely.

Long-term reliance on antidepressants without review is common. Many patients remain on the same dose for years, sometimes decades, without a formal review of whether the medication is still needed. A 2020 audit by the Royal College of Psychiatrists found that only about half of patients on long-term antidepressants had a documented review in the previous year. This raises concerns about unnecessary exposure to side effects and the difficulty of tapering off after prolonged use.

Practical Takeaways for Policymakers and Patients

For policymakers, the most immediate lever is funding. Ring-fenced investment in NHS Talking Therapies could reduce waiting times and expand access, particularly in deprived areas. The NHS Long Term Plan recognised this, but implementation has been slow. Some integrated care boards have used additional funding to pilot shorter waiting times, and early results suggest that targeted investment can make a difference. A 2023 evaluation of the North East and North Cumbria Improving Access to Psychological Therapies (IAPT) pilot, which reduced wait times to under four weeks, found that therapy uptake increased by 20%.

NICE could also clarify its stepped-care pathways more granularly. Current guidelines recommend therapy for mild depression and medication for moderate to severe, but the boundary is fuzzy. More explicit guidance on when to offer therapy first, and on how to combine treatments, could reduce variation in practice. The 2022 update was a step forward, but it left many clinicians wanting more specificity.

GPs need protected time to discuss treatment options. Some practices have introduced “mental health champion” roles or longer appointments for patients with depression. These innovations are promising but not yet widespread. The Royal College of GPs has called for a national framework that gives GPs the time and training to offer shared decision-making.

For patients, the takeaway is to ask about therapy at every review. Even if a referral was not offered initially, it can be requested later. Patients should also ask about withdrawal risks and tapering plans if they are considering stopping medication. Monitoring withdrawal protocols could prevent discontinuation syndrome, which affects a significant minority of patients. The charity Mind provides a useful guide to questions to ask a GP about treatment options.

What remains unresolved is whether the system can ever offer true choice without a fundamental reallocation of resources. The rising prescription rates are a symptom of a system that privileges speed over depth. Until therapy access is truly universal, the debate will continue—and patients will bear the cost of the gap. One open question is whether integrated care boards will prioritise mental health funding in the next spending review, or whether the current trajectory of medication-first care will persist.

This article is for informational purposes only and does not constitute personalised medical advice. Individuals experiencing mental health difficulties should consult a qualified healthcare professional.